2.1.1.56 (2-[4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy)acetic acid - 243374 2.1.1.56 (2R,6S)-2,6-dimethyl-4-[2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine - 243388 2.1.1.56 1,8-dihydroxyanthracen-9(10H)-one - 243456 2.1.1.56 1-(4-tert-butylphenyl)-N-methyl-N-[(naphthalen-1-yl)methyl]methanamine - 243478 2.1.1.56 1-(diphenylmethyl)-4-methylpiperazine hydrochloride (1:1) - 243489 2.1.1.56 1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine - 243490 2.1.1.56 1-[(4-chlorophenyl)(phenyl)methyl]-4-methylpiperazine - 243512 2.1.1.56 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine - 243513 2.1.1.56 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine - 243530 2.1.1.56 1-[bis(4-fluorophenyl)methyl]-4-[(2Z)-3-phenylprop-2-en-1-yl]piperazine - 243531 2.1.1.56 2,3,7,8-tetrahydroxy[1]benzopyrano[5,4,3-cde][1]benzopyran-5,10-dione - 243539 2.1.1.56 2-(2-[4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl]ethoxy)ethan-1-ol - 243566 2.1.1.56 3,3',4',5,5',7-hexahaxdroxyflavone - 243649 2.1.1.56 3,3',4',5,7-pentahydroxyflavone - 37996 2.1.1.56 3,4',5,7-tetrahydroxyflavone - 243651 2.1.1.56 3,8-diamino-5-[3-[diethyl(methyl)azaniumyl]propyl]-6-phenylphenanthridin-5-ium - 243664 2.1.1.56 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate i.e. CHAPS, strong inhibition 109755 2.1.1.56 5',N8-Adenosyl-alpha,beta-diaminobutyric acid moderate 46155 2.1.1.56 amino acid modified structure analogue of adenosyl-L-homocysteine i.e. A9145C, strong 32849 2.1.1.56 aurintricarboxylic acid strong inhibition at 0.025 mM 1818 2.1.1.56 aurintricarboxylic acid - 1818 2.1.1.56 aza-S-adenosyl-L-methionine - 36602 2.1.1.56 bis[6-(dimethylamino)-2-[(E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methylquinolin-1-ium] 4-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylate - 243948 2.1.1.56 Ca2+ strong 15 2.1.1.56 Ca2+ about 10 % residual activity at 5 mM 15 2.1.1.56 carbocyclic aza-S-adenosyl-L-methionine - 63033 2.1.1.56 Cd2+ about 17 % residual activity at 5 mM 52 2.1.1.56 Co2+ about 20 % residual activity at 5 mM 23 2.1.1.56 Cu2+ strong 19 2.1.1.56 Cu2+ about 18 % residual activity at 5 mM 19 2.1.1.56 cycloheximide inhibits protein synthesis in infected BHK cells 1715 2.1.1.56 deoxycholate inactivation 441 2.1.1.56 Digitonin strong inhibition 1615 2.1.1.56 EDTA 12% residual activity at 5 mM 21 2.1.1.56 GpppG inhibits binding of the enzyme to RNA 50765 2.1.1.56 Mg2+ weak 6 2.1.1.56 Mg2+ activation 6 2.1.1.56 Mg2+ strong 6 2.1.1.56 Mn2+ weak 11 2.1.1.56 Mn2+ activation 11 2.1.1.56 Mn2+ strong 11 2.1.1.56 additional information no inhibition by S-uridinyl-L-homocysteine, S-cytidinyl-L-homocysteine 2 2.1.1.56 additional information no inhibition by S-uridinyl-L-homocysteine, S-cytidinyl-L-homocysteine; S-guanosyl-L-homocysteine 2 2.1.1.56 additional information 2'-AMP, 3'-AMP 2 2.1.1.56 additional information inhibition by a natural low-molecular-weight inhibitor in the crude extract, removed during purification 2 2.1.1.56 additional information detergents prevent the association of S-adenosyl-L-methionine with the enzyme 2 2.1.1.56 additional information nilutamide and PPDNS do not display efficient inhibition at 0.025 and 0.125 mM 2 2.1.1.56 additional information GTP and GpppA do not inhibit N7 MTase activity 2 2.1.1.56 N,N-bis-(3-D-gluconamidopropyl)-deoxycholamide strong inhibition 111254 2.1.1.56 N-(2-[[(4-methoxyphenyl)methyl](pyrimidin-2-yl)amino]ethyl)-N,N-dimethylhexadecan-1-aminium - 243999 2.1.1.56 n-octyl-beta-D-gluconpyranoside i.e. octylglucoside, strong inhibition 111459 2.1.1.56 N-tetradecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate i.e. zwittergent 3-14, strong inhibition 111476 2.1.1.56 Ni2+ about 25 % residual activity at 5 mM 38 2.1.1.56 Oligoadenylic acid mono- and triphosphates 2'-5'-linked, with varying numbers of phosphate groups, methylated in the 3'-terminal hydroxy group or all three 3'-hydroxy groups, different types of inhibition of viral and L-cell enzyme 46356 2.1.1.56 ribavirin - 1304 2.1.1.56 S-(2-azaadenosyl)-L-homocysteine moderate 44774 2.1.1.56 S-(3-Aminoadenosyl)-L-homocysteine weak 97090 2.1.1.56 S-(3-deazaadenosyl)-L-homocysteine strong 8188 2.1.1.56 S-(3-deazaadenosyl)-L-homocysteine - 8188 2.1.1.56 S-(8-azaadenosyl)-L-homocysteine weak 12682 2.1.1.56 S-(8-azaadenosyl)-L-homocysteine moderate 12682 2.1.1.56 S-(N6-Dimethyl-3-deazaadenosyl)-L-homocysteine weak 44780 2.1.1.56 S-(N6-Methyladenosyl)-L-homocysteine moderate 15952 2.1.1.56 S-(N6-Methyladenosyl)-L-homocysteine - 15952 2.1.1.56 S-Adenosyl-D-homocysteine weak 4864 2.1.1.56 S-Adenosyl-D-homocysteine - 4864 2.1.1.56 S-Adenosyl-D-homocysteine moderate 4864 2.1.1.56 S-adenosyl-homocysteine - 5733 2.1.1.56 S-adenosyl-L-cysteine moderate 8189 2.1.1.56 S-adenosyl-L-cysteine - 8189 2.1.1.56 S-adenosyl-L-homocysteine product inhibition, competitive 36 2.1.1.56 S-adenosyl-L-homocysteine - 36 2.1.1.56 S-adenosyl-L-homocysteine inhibits methylation of GTP in the presence of 0.005 mM S-adenosyl-L-methionine 36 2.1.1.56 S-adenosyl-L-homocysteine inhibits in a concentration-dependent fashion in the presence of 0.025 mM [3H-CH3]S-adenosyl-L-methionine 36 2.1.1.56 S-Adenosyl-L-homocysteine structural analogues - 45892 2.1.1.56 S-Adenosyl-L-homocysteine sulfone weak 8190 2.1.1.56 S-Adenosyl-L-homocysteine sulfone - 8190 2.1.1.56 S-Adenosyl-L-homocysteine sulfone strong 8190 2.1.1.56 S-adenosyl-L-homocysteine sulfoxide weak 9260 2.1.1.56 S-adenosyl-L-homocysteine sulfoxide - 9260 2.1.1.56 S-adenosyl-L-homocysteine sulfoxide strong 9260 2.1.1.56 S-Aristeromycinyl-L-homocysteine - 10772 2.1.1.56 S-Inosyl-L-homocysteine weak 20507 2.1.1.56 S-Tubercidinyl-L-homocysteine weak 9263 2.1.1.56 S-Tubercidinyl-L-homocysteine - 9263 2.1.1.56 S-Tubercidinyl-L-homocysteine strong 9263 2.1.1.56 sinefungin i.e. A9145, strong 659 2.1.1.56 sinefungin - 659 2.1.1.56 sinefungin inhibits Ecm1 with modest potency 659 2.1.1.56 sinefungin extremely potent inhibitor, binds 900fold more avidly than S-adenosylhomocysteine or S-adenosylmethionine, sensitivity to growth inhibition is diminished when Abd1 is overexpressed 659 2.1.1.56 sinefungin IC50 value 0.00169 microM in yeast cell-based assay 659 2.1.1.56 sinefungin 98.2% inhibition at 0.05 mM 659 2.1.1.56 Thesit strong inhibition 4110 2.1.1.56 Triton X-100 inactivation, reversible by addition of lipids: cardiolipin, phosphatidylglycerol, and especially phosphatidylserine 61 2.1.1.56 Zn2+ strong 14 2.1.1.56 Zn2+ about 30 % residual activity at 5 mM 14